Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | LAP3 | P28838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853461 | 1.00 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL19853299 | 1.00 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL5196443 | 1.00 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL19614462 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL19614467 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL19614463 | 0.98 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| Oxalic Acid SCHEMBL29400639 | 0.97 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL20170560 | 0.89 | SLC1A1 (0.48) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL5196487 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL1631290 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | L-Base Co., Ltd. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4062974-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L BASE CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-4207336-A | AGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| US-4207337-A | ESPECIALLY ANGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| US-4206232-A | Relieving hypertension with carboxyalkylacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4200649-A | Relieving hypertension with carboxyalkylacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1980-04-29 | — | — | US | disclosed |
| US-4192882-A | SUBSTITUTED INDOLES FOR RELIEVING ANGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4192881-A | RELIEVING ANGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4153725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4146641-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4146639-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4105789-A | Carboxyalkylacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SLC1A3 84/4885SLC1A2 42/4885SLC1A1 57/4885 |
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | ATG7, CCL11, ATG13 | SLC1A3 3333/4885SLC1A2 4265/4885SLC1A1 3813/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | SLC1A3 2967/4885SLC1A2 4097/4885SLC1A1 3463/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | SLC1A3 4558/4885SLC1A2 4723/4885SLC1A1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.